Gilead Sciences (GILD) Other Non-Current Liabilities (2009 - 2026)

Gilead Sciences has reported Other Non-Current Liabilities for 18 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 10.25% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (down 10.25% YoY), and the FY2025 full-year result was $896.0 million, up 7.95% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.2 billion, up from $896.0 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $3.8 billion in Q1 2023, with the low at $830.0 million in Q4 2024.
• Historically, Other Non-Current Liabilities has averaged $1.4 billion across 5 years, with a median of $1.2 billion in 2026.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities soared 299.89% — and 2024, when it plunged 63.05%.
• Gilead Sciences' Other Non-Current Liabilities stood at $1.2 billion in 2022, then climbed by 8.57% to $1.3 billion in 2023, then plunged by 35.16% to $830.0 million in 2024, then grew by 7.95% to $896.0 million in 2025, then soared by 33.93% to $1.2 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.2 billion (Q1 2026), $896.0 million (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.